Clinical indicators do not adequately predict the long-term prognosis of patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI). The low-de
Univariable and multivariable analyses for risk factors of failure endpoint in patients treated with tocilizumab and/or methylprednisolone and Standard Of Care (SOC).
